{"id":"tt-00420-tinengotinib","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Anorexia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"TT-00420 (tinengotinib) inhibits several receptor tyrosine kinases including VEGFR, FGFR, and other kinases implicated in oncogenic signaling. By blocking these kinases, the drug suppresses tumor cell proliferation, angiogenesis, and survival pathways. It is being developed as an oral small-molecule therapeutic for solid tumors.","oneSentence":"Tinengotinib is a tyrosine kinase inhibitor that targets multiple receptor tyrosine kinases involved in tumor growth and angiogenesis.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:51:05.015Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT07498478","phase":"PHASE2","title":"Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment","status":"RECRUITING","sponsor":"TransThera Sciences (Nanjing), Inc.","startDate":"2026-03-17","conditions":"Breast Cancer","enrollment":94},{"nctId":"NCT06457919","phase":"PHASE1, PHASE2","title":"A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-06-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT07052253","phase":"PHASE2","title":"A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-07-18","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":100},{"nctId":"NCT07328919","phase":"PHASE3","title":"Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations","status":"NOT_YET_RECRUITING","sponsor":"TransThera Sciences (Nanjing), Inc.","startDate":"2026-01","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Advanced Cholangiocarcinoma","enrollment":138},{"nctId":"NCT06057571","phase":"PHASE2","title":"Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"TransThera Sciences (Nanjing), Inc.","startDate":"2023-11-17","conditions":"Cholangiocarcinoma Metastatic","enrollment":50},{"nctId":"NCT03654547","phase":"PHASE1","title":"Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"TransThera Sciences (Nanjing), Inc.","startDate":"2019-01-08","conditions":"Advanced Solid Tumors, Triple Negative Breast Cancer","enrollment":48},{"nctId":"NCT05253053","phase":"PHASE1, PHASE2","title":"To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"TransThera Sciences (Nanjing), Inc.","startDate":"2022-04-13","conditions":"Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer","enrollment":84},{"nctId":"NCT04919642","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma","status":"COMPLETED","sponsor":"TransThera Sciences (Nanjing), Inc.","startDate":"2021-12-07","conditions":"Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation","enrollment":55},{"nctId":"NCT04742959","phase":"PHASE1, PHASE2","title":"Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"TransThera Sciences (Nanjing), Inc.","startDate":"2021-03-14","conditions":"Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer","enrollment":203},{"nctId":"NCT06370013","phase":"","title":"Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors","status":"AVAILABLE","sponsor":"TransThera Sciences (Nanjing), Inc.","startDate":"","conditions":"Advanced Solid Tumors, Cholangiocarcinoma","enrollment":""},{"nctId":"NCT04705922","phase":"PHASE1","title":"Relative Bioavailability Study and Food Effect Study of TT-00420 (Tinengotinib) Capsule and Tablet Formulations in Healthy Volunteers","status":"COMPLETED","sponsor":"TransThera Sciences (Nanjing), Inc.","startDate":"2020-12-29","conditions":"Healthy","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TT-00420 (tinengotinib)","genericName":"TT-00420 (tinengotinib)","companyName":"TransThera Sciences (Nanjing), Inc.","companyId":"transthera-sciences-nanjing-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tinengotinib is a tyrosine kinase inhibitor that targets multiple receptor tyrosine kinases involved in tumor growth and angiogenesis. Used for Advanced or metastatic solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}